Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$250.6(0.2%)
Market Cap$32.2B
Intrinsic value score
5/10
Good
Intrinsic value
$95.4
DCF value - N/A
Relative value - $95.4
Overvalued
61.9%
LTM P/E
(115.8x)
Peer set median 6.2x
Discount rate
7.4%
ALNY Intrinsic value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY Historical Intrinsic Value
Crunching data... Almost there!
ALNY vs Peer Set: Intrinsic Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
Peter Lynch Fair Value
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Earnings growth model
DCF value calculator
Discount rate
Peter Lynch charts
Reverse DCF
Relative Value
FAQ
What is Alnylam Pharmaceuticals, Inc. intrinsic value?
As of Feb 21, 2025, Alnylam Pharmaceuticals, Inc. Intrinsic Value is $95.4. This suggests it may be overvalued by 61.9% compared to its current price of around $250.6.
What is Alnylam Pharmaceuticals, Inc. DCF (discounted cash flow) valuation?
As of Feb 21, 2025, Alnylam Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $250.6, using a discount rate of 7.4% and terminal growth rate of 3.0%.
Is Alnylam Pharmaceuticals, Inc. overvalued or undervalued?
Alnylam Pharmaceuticals, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $95.4, compared to a market price of around $250.6. This suggests a potential overvaluation of 61.9%.